AnodyneWiki

Oxymorphone

Oxymorphone
Oxymorphone
Salts
[]
Oxymorphone hydrochloride
Oxymorphone hydrochloride
Oxymorphone hydrobromide
Oxymorphone hydrobromide
Oxymorphone hydriodide
Oxymorphone hydriodide
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass301.34 g/mol [1]
AppearanceCrystals from boiling ethanol, ethyl acetate, or benzene [1]
Melting point248-249 °C [1]
Solubility24000 mg/L [1]
Predicted LogP0.8 [1]
Structural Identifiers
[]
Molecular formulaC17H19NO4
IUPAC name(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
SMILESCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
InChIInChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
InChIKeyUQCNKQCJZOAFTQ-ISWURRPUSA-N
CAS number76-41-5
UNII9VXA968E0C
PubChem CID5284604
Pharmacokinetics[]
Elimination half-life10–12 hours[3]
Duration of actionBy mouth: 6–8 hours, Parenteral: 4–6 hours
MetabolismLiver (CYP3A4, glucuronidation)
ExcretionUrine, feces
Routes of administrationBy mouth, buccal, sublingual, intranasal, intravenous, epidural, subcutaneous, intramuscular
Dependence liabilityHigh
Addiction liabilityHigh

Oxymorphone (also known as Oximorphonum, 14-Hydroxydihydromorphinone, Dihydrohydroxymorphinone, Dihydroxymorphinone, Oximorfona, (-)-Oxymorphone, 7,8-Dihydro-14-hydroxymorphinone, Oxymorphonum, Oxymorphone cii or Dihydro-14-hydroxymorphinone) is a opioid substance of the 2-benzylpiperidine class.

Chemistry

Salts []

Oxymorphone is typically found in the form of its hydrochloride, hydrobromide and hydriodide salts.

 []

Oxymorphone is a single defined stereoisomer.

Oxymorphone matches Lipinski's rule of five.

There are currently 4 reagent-interactions on

ReagentColor changeDescription
Marquismagenta > violet
Meckeyellow > brown
Mandelinblack
Froehdeblue > violet

Pharmacology

Mechanism of action []

Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target20 (2 contraindicated)

Medical side effects []

111 side effects listed on drug labels in (oxymorphone).

  • Nausea
  • Vertigo
  • Body temperature increased
  • Constipation
  • Somnolence
  • Headache
  • Vomiting
  • Hyperhidrosis
  • Pruritus
  • Dizziness
  • Syncope
  • Dry mouth
  • Diarrhoea
  • Asthenia
  • Fatigue
  • Insomnia
  • Abdominal pain
  • Gastrointestinal pain
  • Confusional state
  • Feeling abnormal
  • Decreased appetite
  • Anorexia
  • Amnesia
  • Nervous system disorder
  • Convulsion
  • Memory impairment
  • Abdominal distension
  • Anxiety
  • Apnoea
  • Atelectasis
  • Pneumothorax
  • Mental disorder
  • Bronchospasm
  • Chest pain
  • Dehydration
  • Dermatitis
  • Dermatitis atopic
  • Diplopia
  • Drug abuse
  • Dyspepsia
  • Dyspnoea
  • Oedema
  • Eye disorder
  • Flatulence
  • Flushing
  • Gastrointestinal disorder
  • Hallucination
  • Head injury
  • Cardiac disorder
  • Hypersensitivity
  • Hypertension
  • Hypotension
  • Hypotensive
  • Orthostatic hypotension
  • Immune system disorder
  • Laryngeal oedema
  • Laryngospasm
  • Lethargy
  • Lung disorder
  • Mediastinal disorder
  • Miosis
  • Nervousness
  • Feeling jittery
  • Tension
  • Oliguria
  • Palpitations
  • Ileus paralytic
  • Pneumonia
  • Withdrawal syndrome
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Urethral disorder
  • Urinary tract disorder
  • Urticaria
  • Angiopathy
  • Weight decreased
  • Urinary retention
  • Agitation
  • Pain
  • Swelling face
  • Injection site reaction
  • Intracranial pressure increased
  • Biliary colic
  • Urinary hesitation
  • Malnutrition
  • Skin disorder
  • Respiratory rate decreased
  • Disorientation
  • Dysphoria
  • Respiratory depression
  • Pulmonary function test decreased
  • Euphoric mood
  • Vision blurred
  • Cold sweat
  • Sticky skin
  • Bradycardia
  • Respiratory distress
  • Visual impairment
  • Altered state of consciousness
  • Depressed level of consciousness
  • Cancer pain
  • Menopausal symptoms
  • Hot flush
  • Drug interaction
  • Oxygen saturation decreased
  • Mental status changes
  • Ureteral spasm
  • Ileus
  • Mental retardation
  • Mental disability

Indications

  • Acute pain
  • Anxiety
  • Dyspnoea
  • Left ventricular dysfunction
  • Low back pain
  • Opioid naive
  • Pain
  • Postoperative pain
  • Pulmonary oedema

Subjective effects []

 []

  • Australia: Oxymorphone is a Schedule 8.
  • Brazil: Oxymorphone is a A1.[4]
  • Canada: Oxymorphone is a Schedule I.
  • United Kingdom: Oxymorphone is a Class A under the "Misuse of Drugs Act 1971".
  • United States: Oxymorphone is a Schedule II under the "Controlled Substances Act".[5]
  • Germany: Oxymorphone is a Anlage II under the "Betäubungsmittelgesetz (BtMG)".
  • Other: Oxymorphone is a SE: Förteckning II, In general: ℞ (Prescription only).[6]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5284604, Oxymorphone. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5284604
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Oxymorphone. UNII: 9VXA968E0C. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9VXA968E0C
  3. Polsten GR, Wallace MS. Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. 21 June 2016.
  4. Anvisa. RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  5. Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  6. Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Läkemedelsverket. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 11:13:11
drugsprook2026-11-20 11:13:07
erowidmissing (no Erowid substance of that name)2026-11-20 11:13:07
gsrsok2026-11-20 11:13:09
hmdbmissing (hmdb.ca refused automated access to HMDB0015323)2026-11-20 11:13:07
keggok2026-11-20 11:13:09
pubchemok2026-11-20 11:13:06
redditmissing (no r/tripreports posts mention it)2026-11-20 11:13:07
siderok2026-11-20 11:13:07
structureok2026-11-20 11:13:07
wikipediaok2026-11-20 11:13:07